Positive results from 4DMT announce an improvement on BCVA for a dual-transgene treatment for wet AMD and DME.
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), based in Emeryville, California, have announced interim 24-week data from their “PRISM” (WET AMD) and “SPECTRA” (DME) phase I/II… Read More »Positive results from 4DMT announce an improvement on BCVA for a dual-transgene treatment for wet AMD and DME.